# Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated With Ozanimod (RPC-1063)

> **NCT04140305** · PHASE3 · TERMINATED · sponsor: **Celgene** · enrollment: 188 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** RPC-1063

## Key facts

- **NCT ID:** NCT04140305
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-01-16
- **Primary completion:** 2025-05-15
- **Final completion:** 2025-05-15
- **Target enrollment:** 188 (ACTUAL)
- **Why stopped:** Business objective has changed
- **Last updated:** 2025-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04140305

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04140305, "Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated With Ozanimod (RPC-1063)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04140305. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*